Hussey H J, Todorov P T, Field W N, Inagaki N, Tanaka Y, Ishitsuka H, Tisdale M J
Pharmaceutical Sciences Research Institute, Aston University, Birmingham, UK.
Br J Cancer. 2000 Jul;83(1):56-62. doi: 10.1054/bjoc.2000.1278.
The fluorinated pyrimidine nucleoside, 5'-deoxy-5-fluorouridine (5'-dFUrd) has been shown to effectively attenuate the progress of cachexia in the murine adenocarcinomas MAC16 and colon 26 as well as in the human uterine cervical carcinoma xenograft, Yumoto. Although concomitant inhibition of tumour growth was observed in all three models this was not sufficient to account for the preservation of body weight. An attempt has been made to correlate the anti-cachectic activity of 5'-dFUrd with the presence of a tumour produced proteolysis-inducing factor (PIF), thought to be responsible for the development of cachexia in the MAC16 model. Two variants of colon 26 adenocarcinoma were employed, clone 20 which produces profound cachexia, and clone 5 which produces no change in body weight in recipient animals. Mice bearing the colon 26, clone 20 variant showed evidence for the presence of PIF in tumour, serum and urine, while there was no evidence for the presence of PIF in tumour or body fluids of mice bearing the clone 5 tumours. Treatment of animals bearing the clone 20 variant with 5'-dF Urd led to the disappearance of PIF from the tumour, serum and urine concomitant with the attenuation of the development of cachexia. The human cervical carcinoma, Yumoto, which also induced cachexia in recipiant animals, showed expression of PIF in tumour, serum and urine in control and vehicle-treated mice, but was absent in mice treated with 5'-dFUrd. Thus in these experimental models cachexia appears to be correlated with the presence of PIF.
氟化嘧啶核苷5'-脱氧-5-氟尿苷(5'-dFUrd)已被证明能有效减缓小鼠腺癌MAC16和结肠癌26以及人子宫颈癌异种移植瘤Yumoto恶病质的进展。尽管在所有这三种模型中都观察到了对肿瘤生长的同时抑制,但这不足以解释体重的维持。人们试图将5'-dFUrd的抗恶病质活性与肿瘤产生的蛋白水解诱导因子(PIF)的存在联系起来,PIF被认为是MAC16模型中恶病质发展的原因。采用了两种结肠癌26腺癌变体,克隆20会导致严重恶病质,而克隆5在受体动物中体重没有变化。携带结肠癌26克隆20变体的小鼠在肿瘤、血清和尿液中显示出PIF存在的证据,而携带克隆5肿瘤的小鼠的肿瘤或体液中没有PIF存在的证据。用5'-dFUrd治疗携带克隆20变体的动物导致肿瘤、血清和尿液中PIF消失,同时恶病质发展减缓。人子宫颈癌Yumoto在受体动物中也会诱发恶病质,在对照和赋形剂处理的小鼠的肿瘤、血清和尿液中显示出PIF表达,但在用5'-dFUrd治疗的小鼠中不存在。因此,在这些实验模型中,恶病质似乎与PIF的存在相关。